Femara

Letrozole (Femara) 2.5mg — Most Potent AI by Dragon Pharma

Letrozole (Femara) is Dragon Pharma's formulation of the most potent commercially available aromatase inhibitor at 2.5mg per tablet — a third-generation non-steroidal AI that suppresses estrogen by approximately 98-99% at the standard clinical dose. This degree of suppression far exceeds Anastrozole (~85%) and Exemestane (~85-95%) — making Letrozole the appropriate choice when aggressive estrogen suppression is the clinical requirement, and the compound that demands the greatest precision in dosing to avoid the equally significant risks of estrogen deficiency.

Also searched as: Letrozole 2.5mg, Femara, Letrozole AI, Dragon Pharma Letrozole, strongest aromatase inhibitor.

The Three AI Comparison — Where Letrozole Sits

Understanding Letrozole requires understanding its position in the full AI landscape:

Reversible vs Irreversible — The Mechanism Distinction

Both Letrozole and Anastrozole are reversible non-steroidal inhibitors; Exemestane is irreversible:

• Letrozole and Anastrozole bind the aromatase enzyme's active site competitively and reversibly — they occupy the site while present but the enzyme resumes normal function as the drug clears. This means their effect follows their blood level curve closely; stopping the drug restores aromatase activity within days
• Exemestane is a "suicide substrate" that permanently deactivates aromatase molecules — new aromatase must be synthesised to replace the inhibited enzyme. Exemestane's effect persists beyond its blood level half-life
• For Letrozole specifically: the reversible mechanism means its ~98-99% suppression is real-time dependent on sustained dosing. Stopping Letrozole abruptly after extended use produces rapid rebound aromatase activity — estrogen levels can rebound significantly within 48-72 hours if Letrozole is stopped without transitioning to a milder AI

When Letrozole Is the Right Choice — Specific Indications

Letrozole's extreme potency creates specific use cases where it outperforms Anastrozole or Exemestane:

• Gynecomastia reversal: Established gynecomastia tissue (not just glandular sensitivity or puffy nipples) may respond to aggressive estrogen suppression. Letrozole at 2.5mg/day — or even the more cautious 1.25mg/day — is the most commonly cited protocol for attempting to reduce pre-existing gynecomastia tissue through prolonged aggressive AI use. This application requires the deepest estrogen suppression achievable from an oral AI
• High-aromatising cycle control: Cycles involving very high testosterone doses (1g+ weekly), Dianabol at 50mg/day, or combinations of multiple aromatising compounds may overwhelm the suppression capacity of standard Anastrozole doses. Letrozole provides the higher ceiling of aromatase inhibition
• Gynecomastia emergency: Acute gynecomastia onset (tender, swollen breast tissue appearing during a cycle) warrants immediate aggressive estrogen suppression — Letrozole is more effective for acute gynecomastia management than standard AI doses

The Estrogen Crash Risk — Why Letrozole Demands Precision

This is the most important safety consideration with Letrozole and most competitor content handles it inadequately:

• Estrogen is not solely an estrogenic side effect — it is essential for bone density, cardiovascular health, libido, mood, cognitive function and joint health in both sexes. In men, the optimal estrogen range for wellbeing is approximately 20-40 pg/ml
• At 2.5mg/day, Letrozole suppresses aromatase so aggressively that estrogen can drop to near-undetectable levels — producing "estrogen crash" symptoms: severe joint pain, extreme fatigue, depression, zero libido, dry skin and potentially negative cardiovascular effects
• Letrozole at full 2.5mg/day dose is appropriate for breast cancer treatment in postmenopausal women where estrogen suppression is the therapeutic goal. For AAS users managing cycle estrogen, this dose is almost always excessive
• Standard AAS user dosing: 0.25-0.5mg every other day to every third day — a fraction of the clinical dose. Blood panel confirmation of estradiol levels is essential when using Letrozole

Effects and Benefits

• ~98-99% estrogen suppression at 2.5mg/day — the strongest aromatase inhibition achievable from an oral AI
• Gynecomastia reversal potential — the high suppression makes it the most viable AI for reducing established gyno tissue
• Control of high-aromatising cycles where standard AI doses are insufficient
• Mild increase in LH and testosterone through reduced estrogen negative feedback
• Same non-steroidal mechanism as Anastrozole — reversible, competitive inhibition

Dosage and Administration

At 2.5mg per tablet, the tablet can be split for lower doses — 0.5mg = ⅕ tablet; 1.25mg = ½ tablet. Given the potency, starting at the low end (0.25mg every 2-3 days) and titrating based on E2 blood panel is strongly advisable. Letrozole's ~48-hour half-life means blood levels are relatively stable with every-other-day dosing. Do not stop Letrozole abruptly after extended use — transition to a lower-potency AI to prevent rapid estrogen rebound.